Navigation Links
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
Date:4/30/2008

ASHBURN, Va., April 30 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last of three planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for the treatment and prevention of infected diabetic foot ulcers, has commenced dosing. CollaRx GENTAMICIN TOPICAL is a biodegradable and fully resorbable Gentamicin-Collagen Sponge formulated and manufactured using Innocoll's proprietary collagen-based drug delivery technology, CollaRx. Upon application to a wound, the product releases gentamicin, a broad-spectrum, aminoglycoside antibiotic (having a concentration-dependent mechanism of action), for local action. This achieves a high concentration of drug at the target tissue, while maintaining low systemic levels well below the toxicity threshold.

The product is already approved and marketed in Europe and other non-US territories as a surgical implant for the treatment of localized, deep tissue infections and the prevention of surgical site infections in both hard and soft tissues; and is also in Phase 3 clinical development in the US for the prevention of surgical site infections. The development of the topical indication is based upon a series of published clinical case studies and anecdotal reports from clinicians where the marketed implant product has been used topically for treatment of infected chronic wounds of various etiologies. These data support its effectiveness for such clinical applications, particularly in the treatment of infected diabetic foot ulcers.

CollaRx GENTAMICIN TOPICAL is currently under investigation for the treatment and prevention of diabetic foot infections of varying severity in a series of multi-centred phase 2 clinical trials. The first and second trials are investigating the product as a mono-antibiotic therapy for the treatment of mildly infected diabetic ulcers and as an adjunct to sy
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
2. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
4. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
6. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
7. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
8. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
9. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
10. XTENT Announces First Quarter 2008 Financial Results
11. Neuralstem Announces Issuance of Core Technology Patent in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... percent of Americans believe the abuse of strong prescription pain ... safety issue in the United States , ... & Partners, a Cincinnati based research ... the prescription medication abuse problem and the need for medical ... facing our country," Rex Repass , CEO of the ...
(Date:8/21/2014)... 21, 2014 InfinityQS International, Inc., the ... Intelligence , today announces Infusion Chicago, its 9 ... be held Oct. 9-10, 2014, at the Chicago ... showcase the necessity for implementing a quality system ... Intelligence to gain insight into production processes. Complimentary ...
(Date:8/21/2014)... -- Professional Compounding Centers of America (PCCA) will ... three best scientific presentations at the sixth ... Formulating Better Medicines for Children  conference, held ... Greece , includes dozens of poster-style scientific ... three winners will be selected by a panel ...
Breaking Medicine Technology:Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2
... Food and Drug Administration today allowed marketing of the first ... dengue fever or dengue hemorrhagic fever, a leading cause of ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) The dengue ... infected Aedes mosquito. As many as 100 million ...
... 2011 The U.S. Food and Drug Administration today cleared ... assay that is designed to rapidly detect the toxin B ... cause of diarrhea that can lead to colitis, other serious ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Clostridium difficile ( ...
Cached Medicine Technology:FDA Permits Marketing of First Test to Help Diagnose Dengue Fever 2FDA Permits Marketing of First Test to Help Diagnose Dengue Fever 3FDA Clears Test for Bacteria That Can Cause Serious Intestinal Disease 2
(Date:8/21/2014)... Hunhu Healthcare, Inc. , a Minneapolis-based ... it has entered into a licensing agreement with Mayo ... predictive analytics for recruiting, leveraging and managing its solution ... Michael Emerson , co-founder and CEO of Hunhu Healthcare, ... technology used in what he calls a social wellness ...
(Date:8/21/2014)... 2014 Quantum Innovations, Inc . ... to announce the healthcare technology platform, PWeR® 2.0 ... , The company anticipates provisioning its first provider over ... individual physicians, via interfaces, to medical laboratory, pharmacy, secure ... electronic data exchanges and medical clearing houses. , ...
(Date:8/21/2014)... According to new market research report, “Lactic ... Beverage, Personal care & Pharmaceutical) & Polylactic acid ... & Geography - Global Trends & Forecasts to ... markets and segments with analyses and projections of ... sub-segments, in terms of value and volume. It ...
(Date:8/21/2014)... 2014 Being overweight or obese may ... Although there is no cure, patients have learned ... lifestyle changes, such as losing excess weight and following ... is a joint disorder which causes discomfort and pain ... and can significantly reduce one’s quality of life. Although ...
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... wellness in all aspects of life, St. Louis’ Sound ... for the better and revolutionized its online presence. Reorganized ... Mind Café, the new website makes navigating for information ... blue and an easily accessible menu-bar in jet black, ...
Breaking Medicine News(10 mins):Health News:Hunhu Healthcare Enters into Licensing Agreement with Mayo Clinic 2Health News:Grace Century’s Electronic Health Records Project, Quantum Innovations, Announces That PWeR® Healthcare Technology Platform is Ready for Deployment 2Health News:Grace Century’s Electronic Health Records Project, Quantum Innovations, Announces That PWeR® Healthcare Technology Platform is Ready for Deployment 3Health News:Grace Century’s Electronic Health Records Project, Quantum Innovations, Announces That PWeR® Healthcare Technology Platform is Ready for Deployment 4Health News:Lactic Acid Market Worth $3,577.5 Million & Polylactic Acid Market Worth $4,840.1 Million by 2019 – New Report 2Health News:Lactic Acid Market Worth $3,577.5 Million & Polylactic Acid Market Worth $4,840.1 Million by 2019 – New Report 3Health News:Diet Doc’s Medical Weight Loss Programs Announces Safe and Fast Weight Loss That Teach Patients How to Relieve Osteoarthritis Pain 2Health News:Diet Doc’s Medical Weight Loss Programs Announces Safe and Fast Weight Loss That Teach Patients How to Relieve Osteoarthritis Pain 3Health News:Sound Mind Cafe Launches Revamped Website and Hires Hypnotist to Team 2
... researchers say , FRIDAY, April 9 (HealthDay News) -- Children ... vaccines contained both strains of influenza B instead of just ... a second influenza B virus strain to the seasonal influenza ... selection and help improve the vaccine,s ability to prevent influenza," ...
... The commitment to health by country governments in the developing ... to a new study by the Institute for Health Metrics ... Medical School. Overall domestic government spending on health ... billion in 2006, the study shows. That is three times ...
... , ... developer for his own use, this hand polished and sculpted mouse pad is now available ... functional addition to any desktop. , ... (PRWEB) April 9, 2010 -- Dxtra Announces the availability of the world,s only solid ...
... should be paid to prevention and treatment, expert says ... can create serious problems for smokers who have a ... to a new study. , Researchers from Caen University ... nicotine withdrawal can become highly agitated and accidentally remove ...
... ... raise awareness of violence and abuse , ... Washington, D.C. (Vocus) April 9, 2010 -- Children,s National Medical Center,s Teen Life ... artwork designed by youth who have been affected by violence or abuse. , , , ...
... social security fund on a global scale. That is what ... in a Viewpoint in the leading medical journal The ... the use of international donor money a lot more transparent ... cannot be traced in the budgets of the receiving countries. ...
Cached Medicine News:Health News:Flu Vaccine With Both B Strains May Offer Better Protection 2Health News:Developing countries devote more funding to health, except many in sub-Saharan Africa 2Health News:Developing countries devote more funding to health, except many in sub-Saharan Africa 3Health News:Nicotine Withdrawal Can Complicate Hospital Care 2Health News:Children's National Hosts Fourth Annual Youth Anti-Violence Exhibition 2Health News:Children's National Hosts Fourth Annual Youth Anti-Violence Exhibition 3Health News:Why we need a world social health insurance 2
The Model 273 is a general purpose instrument with output that may be either DC-coupled for very slow changes such as venous occlusion and penile tumescence studies or AC-coupled for respiratory or p...
... Plastic and fabric specialty drapes ... gynecology. Steri-Drape absorbent prevention fabric ... fluid strike-through reducing the need ... Drape Pack, Op tape, Hand ...
... top design takes into account a wide ... flexible working environment for the surgical team. ... be matched exactly to your patients height. ... creates superior access for image amplification procedures. ...
... Mitek is the Market leader in soft ... Suture, DePuy Mitek has developed the latest ... open shoulder repair. ORTHOCORD Suture is as ... the market. Most importantly, ORTHOCORD Suture handles ...
Medicine Products: